Acta Medica Leopoliensia (Dec 2021)
ANTIULCER ACTIVITY OF PLACENTAL CRYOEXTRACT IN EXPERIMENTAL INDOMETHACIN-INDUCED ULCEROGENESIS
Abstract
Aim. The side effects associated with the use of indometacin are noted by about 30-60% of patients, therefore, in this context the problem of adverse event rate reduction is still relevant today. Cryopreserved placental extract (CEP) attracted our attention as a means of pathogenetic correction of the ulcerogenic action of indomethacin. The aim of the paper is to characterize the antiulcer activity of cryopreserved placenta extract on a model of indomethacin-induced ulcerogenesis. Materials and Methods. In vivo experimental studies were performed on 28 nonlinear laboratory male rats weighing 200-220 g. Acute indomethacin-induced gastrointestinal injury was replicated by a single injection of indomethacin at 60 mg/kg in rats. Euthanasia of animals was performed after 4 hours after indomethacin administration. Results and Discussion. Macroscopic evaluation of the condition of the gastric mucosa showed that all animals had numerous pinpoint hemorrhages, and 49.2% of rats had mild hyperemia and abnormal folding. Evaluation of the condition of the small intestinal mucosa showed that 57.1% of rats injected with indomethacin alone had 11.1±4.1 ulcers per 10 cm of mucosa length. Prophylactic administration of esomeprazole led to a statistically significant (p<0.05) attenuation of the ulcerogenic effect of indomethacin on the gastric mucosa - the mean score of the mucosa was 3.9 times lower than in control rats and was 0.9±0.26. Conclusions. The combined use of indomethacin and CEP was associated with a 1.9-fold lower ulcer index as compared with rats administered indomethacin only, thus demonstrating the gastroprotective activity of CEP. In contrast to esomeprazole, the introduction of CEP has a pronounced enteroprotective effect, as indicated by the absence of damage to small intestinal mucosa in rats treated with the studied cryoextract and indomethacin.
Keywords
